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Implicit in the growing interest in patient-centered outcomes research is a growing need for better evidence
regarding how responses to a given intervention or treatment may vary across patients, referred to as
heterogeneity of treatment effect (HTE). A variety of methods are available for exploring HTE, each associated with
unique strengths and limitations. This paper reviews a selected set of methodological approaches to understanding
HTE, focusing largely but not exclusively on their uses with randomized trial data. It is oriented for the
“intermediate” outcomes researcher, who may already be familiar with some methods, but would value a
systematic overview of both more and less familiar methods with attention to when and why they may be used.
Drawing from the biomedical, statistical, epidemiological and econometrics literature, we describe the steps
involved in choosing an HTE approach, focusing on whether the intent of the analysis is for exploratory, initial
testing, or confirmatory testing purposes. We also map HTE methodological approaches to data considerations as
well as the strengths and limitations of each approach. Methods reviewed include formal subgroup analysis,
meta-analysis and meta-regression, various types of predictive risk modeling including classification and regression
tree analysis, series of n-of-1 trials, latent growth and growth mixture models, quantile regression, and selected
non-parametric methods. In addition to an overview of each HTE method, examples and references are provided
for further reading.
By guiding the selection of the methods and analysis, this review is meant to better enable outcomes researchers
to understand and explore aspects of HTE in the context of patient-centered outcomes research.
Keywords: Heterogeneity, Risk adjustment, Estimation techniques, Comparative effectiveness researchReview
Background
Recent interest in ‘patient-centered’ outcomes research
(PCOR) stems from a growing need for valid and reliable
evidence that can be used by stakeholders to make indi-
vidualized treatment decisions. Currently, patients, phy-
sicians and payers often make treatment or payment
decisions based upon data representing the average
effect of an intervention, as observed from selected pools
of patients in a clinical trial setting. Reliance on trial
outcomes data for real-world decision making requires
an assumption that the study population from which
the average was generated accurately represents the* Correspondence: richard.j.willke@pfizer.com
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reproduction in any medium, provided the orindividual patient. However, a ‘real’ patient is likely dif-
ferent from the average trial patient in important ways,
such as demographic, disease severity, or health behavior
characteristics.
In terms of intervention outcomes, these differences
could mean that the average effect observed in the study
population may bear little resemblance to the real effect
observed in the individual patient [1,2]. Growing aware-
ness of this phenomenon – known as heterogeneity of
treatment effect (HTE) – has fueled recent discussions
regarding how PCOR studies can be designed to better
account for HTE, so that the results of such research
can guide treatment and insurance coverage decision
making. Given a pressing need to achieve better value in
health care spending, timely HTE evidence can contrib-
ute to both more individualized and more efficient care.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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play an important role in generating PCOR evidence,
there is also an opportunity to more consistently incorp-
orate HTE considerations in the design and analysis of
randomized clinical trials (RCT).
Figure 1 illustrates the impact of HTE on ‘averages’. In
the top portion of the Figure, the treatment effect
(represented on the Y axis) is randomly distributed and
independent of the patient characteristic of interest (the
X axis). In this case, the observed average treatment ef-
fect is consistent, regardless of whether the entire sam-
ple or a subsample similar to the patient is considered.
Thus, in this random effects scenario, HTE does not
exist. In contrast, the bottom portion of the Figure
shows a scenario in which the treatment effect is highly
dependent on the distribution of the patient characteris-
tic. Here, a treatment decision based upon the average
effect observed in the entire sample would underesti-
mate the average effect in the subsample that is similar
to the patient. The treatment decision dilemma regard-
ing whether to expect that the average effect from a trial
will predict an individual’s specific treatment effect is
not novel; but modern methodological approaches have
stimulated renewed efforts to bridge the gap between
the two, recognizing that treatment decisions are a func-
tion of the evidence informing them – and that different
choice(s) may be made when more patient-centered out-












Figure 1 Random Variation in Treatment Effect vs. Heterogeneity of TAssessment of HTE is becoming more common in the
medical literature, often in the form of subgroup analysis
within RCTs [3]. Formal, preplanned subgroup analysis
of RCT data is certainly one means of analyzing HTE
(and is discussed further below), but may not represent
the most efficient or appropriate approach to investigat-
ing HTE. This is because HTE may be the result of com-
plex interactions or latent factors that can only be
unveiled by more elaborate empirical strategies. The
purpose of this paper is to outline a set of key considera-
tions for conducting prospective HTE research through
a discussion of a number of validated HTE methodo-
logical approaches. We systematically address how back-
ground prior beliefs (“priors”) and pre-existing evidence
can shape a methodological approach to better under-
stand HTE. Aimed at study designers with an “inter-
mediate” level of understanding of both statistics and
HTE, this paper provides an overview of select methods
for evaluating HTE. Along with a description of each
method is guidance for their most appropriate applica-
tions. This paper can be used as a starting point for an
audience that may need to factor HTE considerations
into their research plans, but may be unfamiliar with the
full constellation of methods available.
This article is intended to serve as a thorough discus-
sion about how to explore, evaluate and evaluate HTE
evidence, a primer of sorts, for researchers in all sectors
but particularly those involved in product developmentndependent of sample.
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HTE considerations into their RCT studies. Because, for
a given study, aims and circumstances can vary widely,
we have sought to avoid a prescriptive approach to the
process of methods selection. Instead, we seek to provide
the reader with a general framework, supplemented with
sufficient background material that, when combined
with examples and references, enable the researcher who
is interested in developing their own HTE study with
the tools needed to do so.
The HTE methodological approaches discussed below
were informed by a literature review of HTE methods
and selected to provide a review of a variety of techni-
ques in the medical, statistics, and economics literature.
In order to focus on methods useful in product develop-
ment, they were also selected for their apparent rele-
vance to RCT conduct and analysis. Non-randomized
data analyses can inform trial design and real-world
comparative effectiveness research (CER) studies, but
are also subject to treatment selection biases which can
significantly complicate HTE analysis. We considered
such issues beyond the scope of this paper and so non-
randomized data applications are included to a much
lesser degree. Also beyond this paper’s scope is the back-
ground science needed to analyze genetically-driven dif-
ferences, although the HTE methods discussed below
may be used in an exploratory manner in that area.
We begin with relatively established approaches such
as formal subgroup analysis of clinical trial data, and
heterogeneity in meta-analysis of trials. We then discuss
more exploratory approaches for HTE, particularly the
family of predictive risk modeling approaches, with some
detail on classification and regression tree (CART) ana-
lysis. This is followed by several approaches more expli-
citly accounting for intra-individual effects, albeit in
quite different ways – latent growth and growth mixture
models, and series of “n-of-1” trials - with the latter
being an example of how an alternative trial design can
be combined with specific methodological approaches to
model HTE. Finally, we discuss some HTE methods re-
ceiving relatively more attention in the econometrics lit-
erature: quantile-based treatment heterogeneity and
non-parametric methods testing for HTE. The overview
of methods is followed by a discussion of how those with
an interest in PCOR and HTE during product develop-
ment can develop an appropriate research agenda by ap-
propriately matching methods with study questions.
Subgroup analysis of clinical trial data
Widespread in use but contentious in value, subgroup
analysis can assess whether observed clinical trial treat-
ment effects are consistent across all patients, or
whether HTE exists across the patient population’s dem-
ographic, biologic, or disease characteristics. Subgroupanalyses may be pre-specified as part of a trial’s analysis
plan; however, reviews of clinical trial reports suggest
that subgroup analyses are often employed when a statis-
tically significant effect is not detected in the overall
population in an effort to identify a statistical effect of
interest [4,5].
Subgroup analysis should be both undertaken and
interpreted with caution, especially when not pre-
specified [6,7]. One key issue in subgroup analyses is in-
comparability of the subpopulations of interest, which
can arise when the trial’s patient randomization process
has not appropriately taken into account the factors that
define the subgroup [8]. In cases where subgroup ana-
lyses are pre-specified as part of the clinical trial proto-
col, imbalances may be minimized through appropriate
stratification during randomization.
Sample size and power are additional concerns, as
most trials are powered to only detect treatment differ-
ences on the overall population level. Even in cases
where a significant effect within a subgroup is detected,
multiplicity is also a concern, as the likelihood of a false-
positive response increases significantly with each add-
itional analysis conducted [9]. Established adjustment
techniques (such as the Bonferroni, Hochberg, and
related methods) can help to adjust for the multiplicity
issue. However, depending on the number of analyses
conducted, this adjustment, in conjunction with power
limitations, may significantly reduce the likelihood of ob-
serving a true effect [9]. Clear guidance has been devel-
oped regarding the appropriate approaches to subgroup
analyses; these overviews provide a clear framework for
how subgroup analyses should be undertaken [10,11].
Several studies have demonstrated how spurious
results from subgroup analyses can be easily, if inadvert-
ently, generated [7,12,13]. The publication and over-
interpretation of these likely false findings only serves to
increase skepticism around the potential value of sub-
group analyses. Subgroup analyses have greatest value
when used to generate new hypotheses that can be ap-
propriately tested in experimental studies that are specif-
ically designed to test these questions and balance
potential imbalance, power, and multiplicity issues.Meta-analysis
Meta-analysis is a technique that can be used to com-
bine treatment effects across trials and their variations
into an aggregated treatment effect with higher statistical
power than observed in the individual trials. It can also
provide an opportunity to detect HTE by testing for dif-
ferences in treatment effects across similar RCTs. It is
important that the individual treatment effects are simi-
lar enough for the pooling to be meaningful. If there are
large clinical or methodological differences between the
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meta-analysis at all.
HTE across studies included in a meta-analysis may
exist because of differences in the design or execution of
the individual trials (such as randomization methods,
patient selection criteria, handling of intermediate
outcomes, differences in treatment modalities, etc).
Cochran's Q, a technique to detect this type of statistical
heterogeneity, is computed as the weighted sum of
squared differences between each study's treatment ef-
fect and the pooled effects across the studies, and pro-
vides an indication of whether inter-trial differences are
impacting the observed study result [14]. Similarly, tests
such as the I2, H2, and R2 indices developed by Higgins
and Thompson are closely related and measure the de-
gree of statistical heterogeneity [15].
A possible source of error in a meta-analysis is publi-
cation bias, i.e., the likelihood that a particular trial re-
sult is reported depends on the statistical significance
and the direction of the result. Trial size might also re-
sult in publication bias since larger trials would be less
likely to escape publication than smaller, less-known
ones. Language and accessibility might be other factors.
There are methods of identifying and adjusting for pub-
lication bias, e.g. the funnel plot which plots the effect
size against the sample size and if no bias is present is
shaped as a funnel [16]. The 'trim and fill' method is a
non-parametric method of adjusting for publication bias
based on the funnel plot [17,18]. Significance tests such
as the Egger's test and Begg's test can also be used to
identify publication bias [19,20]. Identifying and adjust-
ing for publication bias, in the presence of HTE, has
been shown to be difficult when the meta-analysis is not
large [21]. As has been noted, however, not all HTE is
bad [22]. If the heterogeneity is not a consequence of
poor study design it should be welcomed as a possibility
to optimize treatment benefits for different patient
categories.
HTE can sometimes be minimized by choosing the
measure with the smallest variance across trials. Com-
mon measures of treatment effect when comparing pro-
portions are: the additive Risk Difference (RD), and the
multiplicative Relative Risk (RR) and Odds Ratio (OR).
The RR and the OR both have good statistical properties
but are less intuitive to interpret than the less statisti-
cally efficient RD. It may be the case that one measure,
such as the RR, does not vary across subgroups, while
the RD does vary, and it likely will if a common RR is
applied to different baseline risks [22,23]. In such cases
it is important to determine what type of HTE is mean-
ingful for the purpose at hand.
Meta-regression is a variant of meta-analytic technique
that allows for a more in-depth understanding of the
pooled clinical trial data, by “exploring whether a linearassociation exists between variables and a comparative
treatment effect, along with the direction of that associ-
ation” [24]. As pointed out by Baker et al, meta-regression
should not be undertaken unless there is a sound rationale
for the hypothesis that one, or more, covariates vary
linearly with the treatment effect (e.g. what effect a one
year increase in age has on the treatment effect) [24].
Predictive risk modeling
A rapidly growing method for identifying potential for
HTE is predictive risk modeling, whereby individual pa-
tient risk for disease-related events at baseline is differ-
entiated based on observed factors. Most common
measures are disease staging criteria, such as those used
in COPD or heart failure, as well as more continuous al-
gorithmic measures such as the Framingham risk scores
for cardiovascular event risk [25,26]. Genetic variations,
such as HER2 for breast cancer or cytochrome p-450
polymorphisms, are other such factors [27].
Initial predictive risk modeling, also known as risk
function estimation, is often but not always performed
prior to including treatment effects, and can employ a
variety of methods. This is an area of extensive current
research for more efficient algorithms, given the prolifer-
ating sources of individual patient data with large sample
sizes, better data on outcomes, and large numbers of po-
tential predictors. Traditional least squares or Cox pro-
portional hazards regression methods are still quite
appropriate in many cases and provide relatively more
interpretable risk functions, but are typically based on
linearity assumptions and may not give the highest
scores for predictive metrics. Partial least squares is an
extension of least squares methods that can reduce the
dimensionality of the predictor space by interposing la-
tent variables, predicted by linear combinations of ob-
servable characteristics, as the intermediate predictors of
one or more outcomes [28]. Other, less interpretable
methods include various types of recursive partitioning,
such as random forests, support vector machines, and
neural networks [29-32]. Some of these latter methods,
particularly support vector machines, have been shown
to often have better predictive success than more linear
methods, generally at the expense of clarity of the risk
mechanisms. Risk function estimation can range from
highly exploratory analyses to near meta-analytic model
validation, and may be useful at any stage of product de-
velopment. The better validated the risk mechanism,
however, the more it can be used for hypothesis-driven
rather than exploratory analyses.
Given a risk function that generates pre-treatment
event risk predictions for individual patients, one must
choose how to use it with RCT data to evaluate HTE.
For categorical risk predictions, methods such as sub-
group interactions or stratified treatment analyses can
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Continuous risk predictions can be interacted with the
treatment response in a regression format, but questions
about the nature of the interaction – linear, quadratic,
logistic, etc. – must be managed. Some other techniques
have been proposed as well. For example, Ioannidis and
Lau propose dividing patients into quartiles based on
predicted risks and analyzing accordingly [33]. Lazar et
al propose a technique they term “subpopulation treat-
ment effect pattern plot” that evaluates the effect of risk
on treatment outcomes in a continuous, non-parametric
method, using moving averages over successively higher
risk groups [34]. Crown describes a regression-based de-
composition method that is useful in parsing out risk
factor effects in non-RCT data [35]. With such continu-
ous risk-treatment interactions, if subgroup-determining
breakpoints are subsequently needed for decision-mak-
ing, one approach is post-hoc application of clinically
meaningful treatment effects.Classification and regression tree (CART) analysis
A decision-tree based technique, the Classification and
Regression Tree (CART) approach considers how vari-
ation observed in a given response variable (continuous
or categorical) can be understood through a systematic
deconstruction of the overall study population into sub-
groups, using explanatory variables of interest [36]. In
the context of the various statistical tools that can be
used to understand HTE, CART is a simple approach
best suited for early-stage, exploratory analyses. CART’s
relative simplicity can be powerful in helping the re-
searcher understand basic relationships between vari-
ables of interest, and thus identify potential subgroups
for more advanced analyses.
The key to CART is its ‘systematic’ approach to the
development of the subgroups, which are constructed
sequentially through repeated, binary splits of the popu-
lation of interest, one explanatory variable at a time. In
other words, each ‘parent’ group is divided into two
‘child’ groups, with the objective of creating increasingly
homogeneous subgroups. The process is repeated and
the subgroups are then further split, until no additional
variables are available for further subgroup development.
The resulting tree structure is oftentimes overgrown, but
additional techniques are used to ‘trim’ the tree to a
point at which its predictive power is balanced against
issues of over-fitting. Because the CART approach does
not make assumptions regarding the distribution of the
dependent variable, it can be used in situations where
other multivariate modeling techniques often used for
exploratory predictive risk modeling would not be ap-
propriate – namely in situations where data are not nor-
mally distributed.CART analyses are useful in situations where there is
some evidence to suggest that HTE exists, but the sub-
groups defining the heterogeneous response are not well
understood [36]. CART allows for an exploration of re-
sponse in a myriad of complex subpopulations, and
more recently developed ensemble methods (such as
Bayesian Additive Regression Trees) allow for more
robust analyses through the combination of multiple
CART analyses [37,38].
Latent growth and growth mixture modeling
Latent growth modeling (LGM) is a structural equation
modeling technique that captures inter-individual differ-
ences in longitudinal change corresponding to a parti-
cular treatment. In LGM, patients’ different timing
patterns of the treatment effects are the underlying
sources of HTE. Not only does LGM distinguish patients
who do or do not respond, it also examines whether
the patient responds quickly or slowly, and if they have
temporary or durable responses. The heterogeneous
individual growth trajectories are estimated from intra-
individual changes over time by examining common
population parameters, i.e., slopes, intercepts, and error
variances. For example, each individual has unique initial
status (intercept) and response rate (slope) during a spe-
cific time interval. The variances of all individuals’ base-
line measures (intercepts) and changes (slopes) in health
outcomes represent the degree of HTE. The HTE of in-
dividual growth curves identified in LGM can also be
attributed to observed predictors, including both fixed
and time varying covariates. Duncan & Duncan provide
a non-technical introduction to LGM [39]. Stull applies
LGM to a clinical trial and argues that LGM gives rise
to better parameter estimates than the traditional
regression-based approach and that LGM can explain a
larger proportion of variance [40]. LGM is also closely
related to multilevel modeling [41,42].
However, the assumption that all individuals are from
the same population in LGM is too restrictive in some
research scenarios. If the HTE is due to observed demo-
graphic variables, such as age, gender, and marital status,
one may utilize multiple-group LGM. Despite its suc-
cessful applications for modeling longitudinal change,
there may be multiple subpopulations with unobserved
heterogeneities. Growth mixture modeling (GMM), built
upon LGM, allows the identification and prediction of
unobserved subpopulations in longitudinal data analysis.
Each unobserved subpopulation may constitute its own
latent class and behave differently than individuals in
other latent classes. Within each latent class, there are
also different trajectories across individuals; however,
different latent classes don’t share common population
parameters. For example, Wang and Bodner use a simu-
lated dataset to study retirees’ psychological well-being
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tions exist [43]. They add another layer (the latent class
variable) on the LGM framework so that the unobserved
latent classes can be inferred from the data. Moreover,
the covariates in GMM are designed to affect growth
factors distinctly across different latent classes. There-
fore, there are two types of HTE: 1) the latent class vari-
able in GMM divides individuals into groups with
different growth curves; and 2) coefficient estimates vary
across latent classes. Donald Stull et al apply GMM to
identify and characterize differential responders to treat-
ment for COPD [44]. In comparison of LGM and GMM
focusing on longitudinal data, Luke & Muthen discuss
factor mixture modeling as a method for cross-sectional
studies when heterogeneous populations arise in a simi-
lar fashion as in GMM [45].
Wang and Bodner and Jung & Wickrama provide in-
tuitive introductions to GMM [43,46]. Both point out
that the precision of GMM depends on the number of
predictors included in the model. Moreover, the optimal
number of latent classes needs to be determined. In the
two-step approach they discuss, different criteria, e.g.
Akaike Information Criterion and Bayesian Information
Criterion can be applied for this purpose, but they are
sensitive to sample sizes. GMM also comes with poten-
tial computational burden, and may result in non-
convergence or local solutions.Series of n of 1 trials
Combined (aka, “series of”) n-of-1 trial data provide a
unique way to identify HTE. An n-of-1 trial is a repeated
crossover trial for a single patient, which randomly
assigns the patient to one treatment vs. another for
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Figure 2 Series of N-of-1 Trials, Conduct and Analysis Steps.randomized to treatment for the next time period, usu-
ally repeated for 4-6 time periods. Such trials are most
feasibly done in chronic conditions, where little or no
washout period is needed between treatments and treat-
ment effects are identifiable in the short-term, such as
pain or reliable surrogate markers [47-49].
Combining data from identical n-of-1 trials across a
set of patients allows for a powerful statistical analysis
which can control for patient fixed or random effects as
well as covariate, center, or sequence effects. These com-
bined trials are often analyzed within a Bayesian context
using shrinkage estimators that combine individual and
group mean treatment effects to create a “posterior” in-
dividual mean treatment effect estimate which is a form
of inverse variance-weighted average of the individual
and group effects. These trial conduct and analysis steps
are illustrated in Figure 2. While such trials are typically
more expensive than standard RCTs on a per-patient
basis, the statistically efficient individual-as-own-control
design allows for much smaller sample sizes, often less
than 100 patients, and creates individual treatment effect
estimates that are not possible in a non-crossover de-
sign. For the individual patient, the treatment effect can
be re-estimated after each time period, and the trial
stopped at any point when the more effective treatment
is identified with reasonable statistical certainty [50].
Zucker et al furnish a good example of the information
provided by analysis of combined n-of-1 trials [50]. N-
of-1 trials were conducted for 23 fibromyalgia patients,
comparing amytriptyline with placebo for up to six time
periods. The overall mean difference in the disease
evaluation score was significantly positive but slightly
below a level considered clinically significant. However,
the posterior means of the treatment effect for 10
patients were greater than the clinically meaningfults                                          
= randomize to treatment 1 or 2
= observe outcome of treatment
.
.
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ean for each patient
Figure 3 Quantile Regression Estimation of Treatment Effects.
In the above Figure, quantile regression is used to estimate
treatment effects across a range of survival time quantiles (τ = 0.10,
…, 0.90). For a given quantile τ (horizontal axis), the vertical axis
represents the percent increase in survivorship of Mediterranean
fruit flies associated with an experimental treatment. In part (A),
results for the PappA(−/−) treatment are shown, and in part (B),
results for the bIrs2(+/−) treatment are shown. In each plot, the
middle line represents the calculated effect of experimental
treatments at each survival time quantile, while the upper and lower
lines outline a 95% confidence region. It is clear that in Part A,
treatment effects don’t change with respect to the specific quantile.
However, in Part B, the treatment effects decrease as the quantile
increases.
Reference: Swindell (2009) [57]. Reproduced with permission.
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subset of the patients.
Combined n-of-1 trials could be used for early explo-
ratory testing for HTE, or for later-phase, more focused
testing of comparative effectiveness or cost-effectiveness
[51,52]. While not currently well-accepted for regulatory
purposes, in today’s highly competitive environment
for chronic treatments, n-of-1 trials could provide HTE
information useful in creating phase 3 trial designs
that may lead to evidence more clearly differentiating
new treatments.
Quantile regression
Quantile regression provides additional distributional in-
formation about the central tendency and statistical dis-
persion of the treatment effect in a population, which is
not normally revealed by the conventional mean estima-
tion in RCTs. For example, patients with different
comorbidity scores may respond differently to a treat-
ment. Quantile regression has the ability to reveal HTE
according to the ranking of patients’ comorbidity scores
or some other relevant covariate by which patients may
be ranked. Therefore, in an attempt to inform patient-
centered care, quantile regression provides more infor-
mation on the distribution of the treatment effect than
typical conditional mean treatment effect estimation.
The quantile treatment effect (QTE) characterizes the
heterogeneous treatment effect on individuals and
groups across various positions in the distributions of
different outcomes of interest. This unique feature has
given quantile regression analysis substantial attention
and has been employed across a wide range of applica-
tions, particularly when evaluating the economic effects
of welfare reform [53-55].
One caveat of applying quantile regression in clinical
trials for examining HTE is that QTE doesn’t demon-
strate the treatment effect for a given patient. Instead,
quantile regression focuses on the treatment effect
among subjects within the qth quantile, such as those
who are exactly at the top 10th percent in terms of blood
pressure or a depression score for some covariate of
interest, for example, comorbidity score. It is not un-
common for the qth quantiles to be two different sets of
patients before and after the treatment. For this reason,
we have to assume that these two groups of patients are
homogeneous if they were in the same quantiles. For ex-
ample, Bitler et al [56] make the above homogeneous
distributional assumption and study HTE of welfare
reforms by using the experimental data from Connecti-
cut’s Jobs First waiver. The QTE is measured as the dif-
ference between the inverse cumulative density
functions of the treatment group and the control group.
Another example, based on survival time quantiles, is
shown in Figure 3 [57].The literature on HTE of the impact of welfare reform
has focused on mean treatment effects across demo-
graphic subgroups. This leads us to assume that the po-
tential HTE results from observed differences in some
demographic characteristics. It is possible that the statis-
tical significance of observed HTE from subgroup ana-
lysis is due to some outliers in the dataset, especially
when the number of patients in a subgroup is relatively
small. Quantile regression has the advantage of being
robust to outliers. In a RCT where outliers are a poten-
tial issue, QTE will certainly have the superior perform-
ance compared with subgroup analysis and provide
more convincing evidence for HTE.
Nonparametric methods
Nonparametric methods have a variety of approaches
and advantages for dealing with HTE in RCTs. Different
nonparametric methods, such as kernel smoothing
methods and series methods, can be used to generate
test statistics for examining the presence of HTE. A ker-
nel method is a weighting scheme based on a kernel
function (e.g. uniform, Epanechnikov, and Gaussian).
When evaluating the treatment effect of a patient in
RCTs, the kernel method assigns larger weights to those
observations with similar covariates. This is done be-
cause it is assumed that patients with similar covariates
provide more relevant data on predicted treatment re-
sponse. For patients who have significantly different
backgrounds (demographically, clinically, and context-
ually speaking), kernel smoothing methods still utilize
Figure 4 Nonparametric Regression Estimation of Treatment Effects. Blood-sugar measurements are a common tool in diabetes testing. In a
glucose-tolerance test, the glucose level in blood is measured after a period of fasting (fasting-glucose measurement) and again 1 h after giving
the subject a defined dose of glucose (postprandial glucose measurement). Pregnant women are prone to develop subclinical or manifest
diabetes, and establishing the distribution of blood-glucose levels after a period of fasting and after a dose of glucose is therefore of interest.
The above Figure shows that bivariate nonparametric regression to the mean for glucose measurements for 52 women, with repeated
measurements over three pregnancies. Circles are observed sample means obtained from the three repetitions of the standardized values of
(fasting glucose, postprandial glucose). Arrows point from observed to predicted values. It is clear that different women have different treatment
effects represented by the directions of the arrows.
Reference: Müller et al (2003) [58]. Reproduced with permission.
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mating a particular patient’s treatment effect; however,
lower weights are given to patients who are very differ-
ent. Additionally, kernel methods require choosing a set
of smoothing parameters to group patients according to
their relative degree of similarities. Figure 4 provides an
illustration of how this smoothing can modify individual
estimates [58]. However, the drawback is that the corre-
sponding proposed test statistics might be sensitive with
respect to the chosen bandwidths, which makes the in-
terpretation of results confusing. Series methods use ap-
proximating functions (splines or power series of the
explanatory variables) to construct test statistics. Com-
pared to kernel smoothing methods, series methods nor-
mally have the advantage of computational convenience;
however, the precision of test statistics depends on the
number of terms selected in the series.
Nonparametric test statistics have been proposed in
the literature as powerful tools to identify potential
HTE. Crump et al [59] propose two test statistics for ex-
perimental evaluations of welfare reforms by using thepower series method to test whether the average effects of
a binary treatment are zero or constant over different sub-
populations defined by covariates. Lee proposes a kernel
smoothed nonparametric test for heterogeneity of condi-
tional treatment effects when covariates are continuous
and the outcome variable is randomly censored [60].
The significance of utilizing nonparametric models lies
in the less restrictive assumptions (i.e., differentiability
and moment conditions) imposed in comparison with
the functional form assumptions of their parametric
counterparts. More often than not, the structure in para-
metric models implicitly assumes a homogeneous treat-
ment effect. Therefore, some nonparametric regression
frameworks are flexible in their designs so that they
permit HTE across individual patients. Rather than pro-
viding a p-value for the existence of HTE, the nonpara-
metric regression frameworks may present treatment
effects that vary among patients, from which the distri-
bution of the response to a treatment is observable. The
underlying hypothesis is that differential treatment re-
sponse can be explained by differences in patients’
Determine the level of 
existing evidence of HTE
Step 1 Step 2 Step 3
Strong
Weak or No 
prior beliefs
Consider HTE study design
Treatment(s)
Intent of HTE Analysis 
Study Features
Source(s) of HTE 












• Data Structure 
(cross-sectional, time series, and panel data)
• Data Size Considerations
• Key Strength(s) and  Limitation(s)
• Exploratory Studies for HTE
• Initial Testing for HTE
• Confirmatory Research for HTE 
Figure 5 Decision Process for Choosing a Method for HTE.
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textual variables. Frolich considers a local likelihood
logit model for binary dependent variables [61]. The pro-
posed estimator combines the parametric logit function
with the nonparametric kernel smoothing framework.
The HTE is identified by looking at varying conditional
means and marginal effects for particular changes in the
observable covariates.Discussion and conclusion
Two factors motivated the generation of this primer.
First was a growing recognition of the interest in and
need for more granular and patient-centric data with
which individualized treatment decisions could poten-
tially be made. Second was a realization that there were
no unifying guiding principles for those researchers who
might be interested in exploring HTE as part of a PCOR
agenda.
Figure 5 represents our attempt to build a general
framework around these principles, outlining some of
the considerations that can inform the design of HTE
studies for medical products – particularly pharmaceut-
ical but potentially others such as device or surgical – at
different phases of development. An important initial
consideration in the selection of a HTE methodology is
the level of prior evidence regarding the existence and
nature of HTE for the treatment(s) in question. The
level of evidence may vary widely – for example, early
stage studies may be informed only by biological theory
or by evidence from similar existing treatments, while
post-marketing studies may be informed by original or
subsequent analysis of the phase 3 data, by actual casestudies, or by real world comparative effectiveness
studies.
Once the level of prior information is established, a
second consideration relates to the development of HTE
study objectives. Key elements include the treatments to
be studied as well as the prior evidence about the nature
and sources of HTE, which may be population-based or
treatment-based or both. These will inform the intent of
the HTE investigation, whether it is to be largely ex-
ploratory or testing specific hypotheses. Early stage stud-
ies with little prior evidence may need to be more
exploratory in nature. Subsequent phase 3 studies may
need to determine the most appropriate doses and popu-
lations for initial labeling and may be designed to test
very specific hypotheses already formed by such studies.
Another key element is the nature of the data available
for the study. Existing trial or real-world data may be
sufficient for the intent of the study, or may be the only
study options; otherwise, new data collection may be
part of the study design. Finally, the researcher must
choose the specific method(s) to test for HTE in the
study data. Table 1 provides the most concise represen-
tation of our primer’s intent by arraying key considera-
tions related to the intent of potential data and
methodological needs against each of the seven
approaches discussed above, providing context for when
a given approach might prove most useful. As is often
the case in overviews such as this, it is difficult to de-
clare a single method or two as being the most appropri-
ate for all (or even most) situations in which HTE is
suspected to exist and warrants further exploration. The
complex construct of HTE is made more challenging by
analytic constraints. We have sought to provide clear
Table 1 Features of selected approaches to analysis of HTE
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**QTE: Quantile treatment effect.
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what some of the tradeoffs are when, for example, select-
ing between a post-hoc analysis as compared to an n-of-
1 study. As might be expected, we observe that when
the intent of an HTE study moves from exploratory to
confirmatory, so do the technical challenges associated
with a given methodological approach – in terms of
more complex dataset structures, assumptions related to
distributions, or sample size considerations. It seems safe
to say then that the appropriate selection of a statistical
framework for a given HTE research question should
seek to weigh the level of existing evidence of HTE
against these intent and methodological burden factors,
and that in any reporting of HTE study results, study
findings should be contextualized against the approaches
used to derive them. In addition, for the benefit of those
who would like to explore specific analytical tools for
these approaches, we provide notes on some available
estimation routines in well-known software in an
Appendix.
The importance of ‘context’ for HTE studies goes be-
yond just methodological concerns. The recent and
growing interest in patient-centered treatment meansthat HTE studies are increasingly likely to be used in
clinical decision-making. However, the hope that HTE
evidence can serve to significantly improve patient out-
comes needs to be balanced against questions regarding
the reliability of the scientific methodology used to iden-
tify the HTE in question, the weight of what is already
understood about conditions in which HTE studies are
developed, and new concerns that may arise as add-
itional HTE evidence is generated.
An example of such a concern is whether it is suffi-
cient to be able to detect that a given population
responds differentially to a treatment. What if this differ-
ential response is novel, was not previously detected in
prior attempts at HTE investigation, but was only dis-
covered using a relatively new statistical technique?
Should those patients who reflect the differential re-
sponse population be treated differently – and if so,
how?
The key question facing researchers and policy makers
is as follows: what level of evidence is required before
treatment paradigms may change on the basis of HTE
data, and how do we understand and accept the validity
of this evidence in a landscape where new tools for
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tion is only likely to become more urgent as increased
availability of electronic data sources yields more and
more research that could profoundly impact clinical
treatment paradigms. While there is great hope that re-
cent efforts like those being undertaken by the Patient
Centered Outcomes Research Institute will result in the
development of better evidence and improved decision-
making ability for all stakeholders, significant work is
needed to standardize and build consensus around
which methods are most appropriate to be used to gen-
erate this evidence.
Despite the high levels of enthusiasm and funding
directed towards evidence generation, key questions
regarding dissemination and assimilation of evidence
into clinical practice remain. In the case and context of
HTE studies, it will be crucial to further understand
what types of analyses are most likely to impact clinical
decision-making behavior. By contextualizing various
existing HTE methods that could potentially be used
against a novel framework, which highlights both prior
evidence as well as other considerations related to ele-
ments of study design, this primer sought to fill what
seems to be an increasingly important gap in the out-
comes research literature.
Appendix – notes on estimation routines
Standard meta-analysis like fixed and random effect
models, and tests of heterogeneity, together with various
plots and summaries, can be found in the R-package
rmeta (http://cran.r-project.org/web/packages/rmeta). Log-
istic regression and survival model routines, both basic
approaches to predictive modeling, are found in all major
statistical packages (e.g., SAS (Proc Logistic, . . .), Stata
(logistic or logit, stcox, etc.). Routines for calculating
empirical Bayes shrinkage estimates for n-of-1 trials
are available in S-Plus, with more general Bayesian
approaches available in WinBUGS or in R with R2Win-
BUGS. Basic quantile regressions can be estimated in
Stata with the command qreg or in SAS using Proc
Quantreg, although some additional programming is
needed to generate the full range of quantile estimates.
The linear regression decomposition approach can be
implemented in Stata with commands decomp, decom-
pose, and Oaxaca. For non-parametric approaches, R offers
many available routines, which are well-documented at
http://cran.r-project.org/web/packages/np/vignettes/np.pdf.
In SAS, Proc NLMIXED and Proc TRAJ are available for
the estimation of LGM/GMM; in Stata LGM is handled
within the sem command.
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